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Abstract-A
longitudinal panel study examined the effects of actual use of diazepam (Valium" ) on subjective reports of life quality, affect. performance, stress, social support, control. coping and other variables related to mental health. Standardized interviews were conducted with 675 persons from the Detroit Metropolitan
Area. Based on prescription records, diazepam users and nonusers were selected to represent a variety of sociodemopraphic characteristics rather than lo be a completely random sample. Significant pthers in work and in personal life were also interviewed. Four interviews took place. one approximately every 6 weeks. Testing for social effects was conducted by within-and across-person analyses of 367 respondents who reported taking the medication at some time during the study and by comparisons with 308 respondents who did not report taking Valium. Users of Valium tended 10 take less Valium than prescribed.
They also reported consuming less alcohol when using Valium than at other times and less than non-Valium users. Although there was a modest. positive cross-sectional relation between Valium use and distress. numerous multivariate analyses controlling for levels of stress and health indicated no notable effects of Valium use on any of the social or psychological indicators. including anxiety. Several interpretations of the results are examined including the possibility that the effects of Valium use were short-lived rather than long-term and that Valium may have been taken in anticipation of anxiety rather than after its occurrence.
INTRODUCTlON
A large body of clinical trial literature has demonstrated the anxiolytic properties of benzodiazepines (for an extensive review. see Greenblatt and Shader [I] ). At the same time, there has been controversy regarding the social and psychological effects of minor tranquilizers as used in society [2-41. Despite this controversy, there has been little systematic research on the social effects of r~pical use. This study addresses this controversy by examining typical use, rather than use in a clinical trial, and by focusing on long-term effects with a longitudinal panel design.
The study examines the consequences of tranquilizer use in people who were nbt participating in clinical trials. As necessary substitutes for the randomization and pre-experiment washout periods of formal clinical trials. the study uses multivariate statistical modeling techniques to capitalize on natural variation in tranquilizer use.
Previous large-scale survey research on psychosocial correlates of anxiolytic use has been crosssectional [5.6] . Such studies were not designed to distinguish among the antecedents, noncasual correlates and consequences of using minor tranquilizers. This study used a longitudinal survey design to search for consequent, relatively-enduring social effects such as changes in the ability to cope, in sense of control, and in the well-being of significant others such as a spouse. The study attempted to address social concerns about relatively permanent rather than transitory social effects of tranquilizer use [24] , and so the design precluded detection of short-term effects such as relatively immediate (e.g. within hours) effects on affect, well-being or performance.
Focus on Valium
In order to examine the correlates of variation in the pattern of tranquilizer use efficiently, a single brand of medication was studied. Diazepam (Valium " ) served this purpose best because it was the most commonly prescribed tranquilizer in the United States [7] , and is frequently mentioned as an example of a minor tranquilizer in the literature. Throughout the text, the proprietary name 'Valium' will be used because this is the way respondents referred to diazepam. No endorsement whatsoever is intended by this usage.
Theoretical jiiamework
Several basic hypotheses guided the study. One was that environmental stress, or demands and threats in personal and in work life, and the demands and threats of illness increase emotional strain such as anxiety [8] . Stress was also predicted to reduce life quality and performance. These hypotheses have been supported by numerous studies on how life 887 events as well as day-to-day events and conditions influence emotional well-being and behavior (e.g.
19, 111).
It was further hypothesized that coping by changing how one viewed the problem, by expressing or controlling one's emotions, and by dealing directly with the cause of the problem could reduce stress. strain or the relation between them depending on the target of the coping. If Valium use alters the ability to cope. it could. in addition to having direct anxiolytic effects, indirectly influence all the abovementioned effects of coping. The study also examined whether the use of Valium influences the well-being of persons around the user. For example, the well-being of a spouse or a co-worker, and their ability to provide social support [l6], might be influenced by the emotional state of the user and by any effects that Valium use might have on the ability of the user to cope with daily problems.
This framework suggested a variety of outome variables, referred to as potential social effects. These included sense of control, provision as well as elicitation of social support.
affective states (anxiety, depression, anger), perceived quality of life (satisfaction), the use of alcohol, caffeine, and other drugs and ability to manage one's emotions and to perform responsible roles in work and personal life*. The well-being of significant others, noted above, also constituted an outcome variable. This study examined a large number of such hypotheses including the above examples. A large number of analyses were generated to test all the derived predictions.
The text necessarily focuses on the main points of the methodology that was used and of the results that were producedt.
METHOD

Overaiew
In a panel survey design. 675 people. 17 years or older were interviewed four times, once every 6 weeks, covering a 6-month period, Of these persons. 367 reported using Valium at some time during the course of the study; the remaining 308 did not report using any tranquilizer during the course of the study. Characteristics of the respondents are presented below.
Respondent selection
The Michigan Board of Pharmacy, under state law. reviewed the study protocol and authorized the investigators to obtain the names, addresses and telephone numbers of clients of pharmacies that agreed to participate in the study. The set of respondents was intended to include various demographic groups (to permit subgroup analyses) rather than to be representative of the population.
Consequently the pharmacies were drawn from the greater Detroit metropolitan area in a random sample stratified to represent a broad range of neighborhoods with regard to sociodemographic characteristics. Males, females and members of different age groups were quota-sampled from the pharmacy records so as to have sufficient numbers for analyses within each subgroup.
Previous research had found that users of anxiolytics report more illnesses of all types compared to nonusers [6] . For this reason, it seemed best to draw nonusers as well as users of Valium from recent pharmacy records in order to reduce initial differences in health between the two groups (compared to what it might have been if nonusers had been sampled from the community).
To this end. pharmacy clients were sampled if they had filled a prescription within the prior 6 weeks, either for Valium or for a nonpsychotropic drug. The 6-week period was required to obtain a sufficient number of Valium users in the sampled region. Persons were excluded from the nonuser (nonpsychotropic) group if they had received a prescription for other antianxiety agents, antidepresents, antipsychotics or. because of their CNS-depressant effects, antihistamines. Seventyseven persons were excluded because they were either foreign speaking. too ill. or too senile. It was not possible to compare the original 2070 persons with the final set of respondents on age or gender.
Multi-item indices of social and psychological variables were used to increase the reliability of measurements. These indices generally had coefficients of internal reliability (alpha) in the 0.70s and 0.80s. The reliabilities of the measures replicated in a variety of subgroups (e.g. males, females, Valium users and nonusers, high and low education) and across all four waves. for a national random sample of users and nonusers of minor tranquilizers. This figure is for persons reporting an> use in the past year. It is not possible to distinguish in those data between current users. as defined in this study. and past users of an anxiolytic medication. a category which must describe the large majority of respondents in such a study [lg. 61. Nor is it possible in those data to distinguish between respondents currently being treated for an illness. which was likely to characterize nonusers in this study. and respondents not being treated.
Unless noted otherwise, all interview questions referred to conditions during 'the last 7 days'. Anxiety, depression and somatic complaints were measured using relevant items from the Hopkins Symptom Checklist [20] . The Hopkins Checklist was used to assess changes in relative levels of anxiety symptomatology rather than to render a specific categorical diagnosis of anxiety.
Measures of quality of life [21] and of stress [I I] were drawn from standard measures in the literature. Other measures of coping, control, performance and social support were developed and pretested for reliability prior to use in the study [22, 23] . The Appendix provides some examples of these measures, and the complete content of the indices is available elsewhere [ 171.
It was possible to examine the consensus between two observers because both the significant other and focal respondent reported on the focal respondent's performance, quality of life, social support, and social conflict. Data from Wave 1, which are typical, showed that there was good consensus in some domains and not in others. For example, the focal respondent's ratings of overall quality of life and of worklife were moderately to strongly correlated with ratings by the personal and work others (0.61 and 0.44 respectively).
The focal respondent's ratings of technical and social performance in personal life correlated 0.18 and 0.25 with the respective ratings made by the personal life significant other. In the work life domain, the respective correlations were 0.09 and 0.30.
Given the generally good internal reliabilities for the measures from the focal respondent and the significant others, the low correlations between the two sets of respondents suggests that each type of person represents a different perspective. Each perspective perhaps is the product of particular bias and access to different information.
A detailed history of drug use in the prior 6-weeks was obtained, as was some information regarding use in the prior year. Particular detail was pursued with regard to consumption of frequently used medications which have either CNS-stimulant or -depressant effects. Seventy-five percent of the data regarding prescribed dosages of medications was recorded from medicine bottle labels; the remainder was based on respondents' memories. Distinctions were made in the coding and analyses of these data between 'use as needed' (PRN) prescriptions and fixed schedules. In addition, respondents were asked for retrospections about use of Valium, anxiety, and quality of life for each of the 6 weeks preceding each interview. At Waves 2-4 they were also asked for retrospections regarding the seventh prior week, which was the week of the preceding interview; this allowed checks on the accuracy of retrospection. These weekly data on Valium-taking, anxiety, and life quality were obtained on a form that resembled a calendar; they are referred to below as 'calendar measures'.
These retrospective calendar measures were found to be reasonably accurate. Restrospections at Waves 2, 3 or 4 correlated on the average with matched data collected at the previous wave in the range from 0.5 for anxiety to 0.8 for Valium-taking.
Recall may have been good for two reasons: (a) the phenomena may be relatively stable and (b) we worked at improving recall by first asking respondents to recall an event that stood out in their lives for each week.
Churucteristics of' respondents
As noted. the intent was not to draw a random sample of the population.
Nevertheless, comparisons with the 1979 U.S. Census Data [24] indicated that the respondents were similar to the U.S. population with respect to the distributions on sex, age and education. The mean age for the respondents was 46. Average education was I2 years. Average family income was in the range of $15,000 to $24,999 per year. Fifty-four percent of the respondents took Valium at some time during the study.
To provide sufficient numbers of both sexes among the Valium users. the proportions of male and female users in this study (39 and 61",,. respectively. at Time 1) were more equal than those found in national sample surveys [6. 191. Among nonusers. 46",, were male, 54", were female. The higher proportion of Blacks (2l"J than found nationally (lo",, [24] ) reflects the demography of the Detroit metropolitan area. Valium users tended to be slightly older. less educated and have less income compared to nonusers. Valium users also reported lower subjective quality of health, higher anxiety, higher depression. and lower subjective quality of life. Such differences reflect the association between distress and use of anxiolytic drugs found in random sample surveys of the U.S. population [5. 61. Comparisons with nationwide prescription surveys [25] showed that, as in the country as a whole. respondents in this study were prescribed Valium most often by physicians in general practice or in internal medicine; osteopaths and psychiatrists were the next most likely to prescribe this medication. With regard to physical health, users of Valium in this study were similar to those in a recent national random sample [6] . Users were four times as likely to report some health problem as nonusers in this study even though the nonusers were pharmacy clients too. Users in this study, like those found in the national sample, were more likely to report chronic illnesses such as high blood pressure and arthritis whereas nonusers were more likely to report acute medical problems. 
RESULTS
Ooeroiew t3f Vulium use
Anxiety, tension, keeping calm or keeping relaxed were mentioned by 70'!,, of the respondents as reasons for taking Valium; insomnia was mentioned by 17'::;; and the only commonly mentioned physical reason was a pulled back or sore muscles (9':/,). Note that these were respondent reports rather than diagnoses from medical records.
The most commonly prescribed doses of Valium ranged from IO to 20 mg per day. Fewer than 91, of prescriptions were for 30 mg or more per day. Patients prescribed specific regimens (i.e. not PRN) tended to take less rather than more milligrams than prescribed, replicating prior research on compliance with anxiolytic treatment [26] . The most commonly reported actual usages ranged between 2 and I5 mg per day (8892) a range within guidelines described by the Valium package insert [27] . Only two persons reported taking more than 40 mg per day at Wave 1.
The large majority (83%) of persons taking Valium within the 6 weeks preceding each interview also reported taking the medication within the seven days prior to each interview. The majority of Valium users (59%) took some Valium during all four of the 6-week periods prior to each interview. Nevertheless, there were considerable ranges of doses and patterns of use across and within the 6-week periods between interviews. During the 6 weeks preceding the Time 1 interview, 33% of the users of Valium reported taking the medication 'only once in a while', almost half (47%) reported taking it 'every day or every other day the whole time' and the remainder took it either 'some weeks almost every day, other weeks not at all' (1 I",/,) or at more evenly spaced intervals which were less frequent ('at least once a week the whole time'; 9"/,). The distributions of pattern of use at Times 2-4 were similar to that at Time 1.
The number of drinks of alcohol consumed by Valium users compared to nonusers was about the same (e.g. at Wave 1, the respective means were 5.7 and 6.1 drinks per week; the respective standard deviations were 14.2 and 11.9). (Although comparable national sample data are not available, a 1979 survey [37] showed that 33'6 of the population were nondrinkers, and among the drinkers, 'heavier' drinkers were classified as consuming more than 40 drinks per week. The averages in this study fall well below that level.) Persons who took Valium daily were less likely to consume alcohol than nonusers (e.g. 48y0 compared to 669,; of the nonusers at Wave 1. P < 0.01). but among those who drank any alcohol at all during this period. there was no difference in the amount of alcohol consumed. The design of the study does not allow one to determine the extent to which the differences in the percentage of drinkers among daily Valium users and nonusers was due to selfselection. substitution of Valium with alcohol (and vice-versa) or compliance with physician recommendations regarding the use of alcohol and Valium simultaneously. Valium users also tended to smoke more cigarettes than nonusers. but Valium users and nonusers did not differ with regard to use of caffeine or street drugs. Street drug use was very low among all respondents. and there was no evidence that Valium use led to use of street drugs. Valium users tended to take more prescribed nonpsychotropic drugs than did nonusers.
Valium users reported that their prescribing physicians were generally supportive. a finding counter to the criticism that tranquilizer prescribing indicates some physicians' relative inattention to the psychosocial needs of patients (281. Lastly. Valium users reported that the medication helped them control their lives, although there was no statistical relation between the amount of Valium taken and users' scores on various measures of control.
Sociul c$hcts of Vulium use: primury unulyses
Results of bivariate analyses are described first. They are followed by results of multivariate analyses that introduce various statistical and subgroup controls.
Correlutionul, lugged unulyses. Using the weekly retrospective calendar data, it was possible to examine how ratings of quality of life and .anxiety correlated with Valium use when Valium use and these other variables were measured simultaneously, and when Valium use was measured before (i.e. l-24 weeks before) and after (i.e. l-24 weeks after) quality of life and anxiety. The measure of Valium use employed in these and most other analyses reflected the total number of milligrams taken each week. correlation being about 0.14. Conversely, the average zero-lag correlation was about -0.12 between Valium-taking and quality of life. and the correlation was always negative regardless of the lag-i.e. poor quality of life was associated with the use of Valium. For both quality of life and anxiety, the simultaneous relation with Valium-taking tended to be slightly stronger than most of the lagged relations. The correlation between quality of life and anxiety was -0.52 at lag 0 and decreased by weeks 4-6 in the range -0.1 to -0.2. The relation declined only slightly more with lags beyond 6 weeks. These results suggest that if causal relations existed, they were more likely td occur within the 7-day span of the measures rather than across longer intervals.
Lagged relations were also examined using data from the other portions of the interview. referring to levels of Valium use, anxiety, quality of life, and other social-psychological variables in 'the last 7 days' prior to each of the four interviews. for correlated measurement errors (e.g. when a predictor and a dependent variable are correlated because they are measured with the same procedure), and for potentially confounding variables, including the differences between users and nonusers of Valium in initial levels of anxiety. perceived stress, and perceived physical health. We believe the modeling approach provides the best available estimates of the effects of Valium use because of these controls*.
Using this approach. the investigator specifies a set of hypotheses, referred to as the model, and tests how well the data conform to the modell-. The model in Fig. 2 was the best of several models in terms of its ability to describe the actual relations in the data, the theoretical reasonableness of the parameter values, and the theoretical reasonableness of the obtained structuref.
For example, health was modeled as increasing stress, and both stress and health were modeled as increasing anxiety. Anxiety, in turn, was modeled as leading to the comsumption of Valium and to decrements in performance in personal life. And poor health, high stress amd'anxiety, and low performance were, in turn. modeled as producing a decrease in perceived quality of life as a whole. Valium was modeled as having effects on performance and quality of life-as-a-whole via the effects of Valium on anxiety. And most of the concepts were modeled to allow for direct effects on themselves at later times.
In Fig. 2 , the constructs are represented by ovals. The measures of the constructs are represented by rectangles. The subscipt within each oval or rectangle represents the particular wave of data collection. Arrows between ovals represent estimates of the strength of relations between constructs after controlling for measurement error (e.g. at Wave 2, the strength of the relation between health and anxiety is -0.44).
The arrows from ovals to the rectangles represent the effects of each construct on how people answer the questions about the construct; hence. they reflect the validity of the questions (e.g. anxiety is reflected at Wave I in the calendar measure with a validity of 0.58 and in the Hopkins measure with a validity of 0.79). In this particular model. the data at Waves 2-4 merit the closest attention because they take into account prior (i.e. from the previous interview) levels of stress, health. Valium use. performance and quality of life. The model shows a number of reasonable relations within the last three waves. For example, and as expected, poor health and stress preceded increased anxiety (coefficients ranged from -0.18 to -0.44 and from 0.67 to 0.82, respectively). Anxiety had negative effects on performance in personal life (-0.20 to -0.27) and on quality of life as a whole (-0.44 to -0.55). Performance had a positive effect on quality of life (0.33-0.39). Health and stress were generally unrelated.
The current levels of anxiety and of life quality in this model were attributed mainly to the current levels of the other constructs, with little or no direct effects from six weeks earlier. Although the model allowed for the possibility that Valium-taking would have an effect on anxiety 6 weeks later, and, through anxiety, on performance and life quality, these links were zero or near zero*.
These results provide one of the more important findings of the study-an explanation for the positive relation between Valium use and psychic distress found in cross-sectional studies [5. 61, as well as in this study's bivariate analyses (see above). Once prior levels of anxiety, health and stress were controlled. there was no relation between Valium use and anxiety either cross-sectionally or over time. These controls also led to the near-zero effect of anxiety on Valium-taking at Waves 2-4. This finding suggests the following interpretations: Whereas a high level of anxiety may lead to a prescription for Valium (or any other anxiolytic). continued use may not be triggered by anxiety under the following conditions:
when the person (a) uses the medication daily because of instructions from the physician or *The effect of Valium use on subsequent level of quality of life can be computed by multiplying the coefficients along each causal path that links Valium use to quality of life and summing the products.
The same procedures can be followed for computing the link between Valium use and performance.
These products are all very small because the Valium-anxiet) link is weak, based on habit. including the habit of preventive or anticipatory use or (b) uses the medication nondaily for the management of anxiety that lasts only for a brief period such as a day. With regard to the first condition, although almost 5O'J, of the users of Valium were daily users at each of the waves, the study was not designed to examine preventive or anticipatory use. With regard to the second condition. the measures of Valium use and of other variables were not designed to detect the elfects of such highly transitory use, but, rather, were designed to summarize time periods of at least 7 days. Further research will be required to evaluate the validities of these potential interpretations.
Social t$kcts of Valium use: supporting ana!)ws
Subgroup analyses. Although there was no evidence of either harmful or beneficial social effects of Valium use when all study participants were analyzed together, it was possible that some social effects might appear for specific subgroups of respondents. Subgroups were formed in a number of ways: by whether Valium had been taken for anxiety or for other -reasons, the amount of social support the person reported receiving from the Valium-prescribing physician and others, gender, daily use versus other patterns of Valium use, use of other medications. perceived internal control, attitudes towards tranquilizers, demographic variables, use of coping techniques, health, and other stressors of life. Over 6000 analyses examining various lags were performed across the several waves of data. No evidence was found for subgroup effects beyond those due to chance.
Another search examined the extent to which Valium use either buffered (reduced) or exacerbated (increased) the relations between stresses and quality of life or other outcomes, such as anxiety, depression. performance and perceived control. Although there was a slight tendency for Valium use to buffer such relations, the magnitude of the effect was generally weak, did not replicate well across waves. and was offset by some instances in which Valium use seemed to exacerbate effects of stress on other outcomes. Analysis of covariance. This set of analyses, like the structural modeling analyses, controlled for the higher levels of perceived stress and poorer health among users of Valium. Some of these analyses selected small subsets of both users and nonusers of Valium who had high initial levels of anxiety on the Hopkins Checklist-levels typical of those found at the start of treatment in clinical trials. Three separate sets of analyses were performed:
(1) for dai/y users (highly anxious persons who reported taking Valium daily or nearly daily during the 6 weeks prior to Wave 1 through Wave 2-a period of about 12 weeks), (2) for new users (persons who reported taking Valium for the first time during the 6-week period prior to Wave 1) and (3) for highly anxious nonusers. With these restrictions, the number of new users was only 19, and the number of cases for the other two groups was about 50 (the sample size varied depending on the variables analyzed).
These analyses examined the effects of Valium use on performance, anxiety, depression, the well-being of the personal other, and many other variables. No 
Other findings deuling with sociul &c.ts
Elsewhere it has been suggested that the use of minor tranquilizers may dull the user's sense of the external environment and its stresses and may numb normal emotional reactions so that users are not able to report their feelings to others [32] . The data from this study do not support these conjectures. The statistical relations between stress and emotion for users and nonusers were generally the same across most waves. Furthermore, changes in stress and in emotion over the four waves of the study among the nonusers were paralleled by similar changes for the users of Valium (stress declined in personal life and in work life. and emotional states improved for both groups with no statistical differences between the groups after controlling for initial levels). Among users of Valium. the higher levels of stress. including poor health, were accompanied by higher levels of negative affect-a normal emotional response in the sense that nonusers of Valium also showed similar response sensitivities.
DISCUSSION
Overall, this study found little evidence that use of the minor tranquilizer Valium had any social effects, either harmful or beneficial.
Although there were small, positive cross-sectional relations between indicators of distress and use of Valium, these relations were near zero over time when statistical controls were introduced for prior conditions of stress and health. A lesson of these analyses is that it is important to consider the stabilities and the antecedent effects of variables which are likely to influence the use of anxiolytics and potential outcomes of anxiolytic use such as anxiety and quality of life.
It was conceivable that the findings might have been an artifact of a particular statistical method of analysis. For this reason, multiple techniques were used for examining the data across as well as within persons. Each analytic method allowed us to take a different perspective on the data. The results were similar across all of the methods.
With regard to other social issues, users of Valium perceived their prescribing physicians as socially supportive rather than unsupportive.
There was no evidence that Valium use numbed emotional responsiveness:
the relations between social stresses (e.g. role conflict at work) and emotions (e.g. anger) were the same for users and nonusers of anxiolytics.
Although the study was not designed to examine drug abuse, it was evident that there was little use of street drugs among these respondents as a whole, no difference between users and nonusers of Valium with regard to the use of such drugs, and a tendency for users of Valium to take less rather than more than the amount of Valium prescribed. This tendency toward undermedication with minor tranquilizers has also been noted in clinical trials [33] .
Interpreting the longitudinal.findings
This study was designed chiefly to examine social effects of the use of Valium. The fact that no major social effects were detected requires explanation.
It was hypothesized that.social effects might occur either directly or indirectly as the result of Valium use. If brought about indirectly, such effects might have been the secondary result of a reduction in anxiety, which is typically found in clinical trials [I] . Thus, this study's finding of no major social effects might be explained by its corresponding finding of no lasting effects of Valium use on anxiety. Consequently, it is worth examining why the study detected no anxiolytic effects of Valium use.
One possible reason why Valium use was not found to reduce anxiety is that the Valium users in the study may not have taken sufficient doses of the medication. However, although users of Valium did tend to take less Valium than prescribed, the amounts they took are considered adequate to produce anxiolytic effects and fall within the recommended doses described in the package insert. Nevertheless, we conducted separate analyses for persons who took different doses or had different patterns of use (e.g. daily vs intermittent) and the findings remained basically unchanged. Thus, low dose does not provide an explanation.
What other factors might account for the lack of any detectable anxiolytic or social effects?
As noted at the outset, this study was designed to search for long-term rather than transitory (e.g. those that might occur only for a day or so after taking the medication)
anxiolytic and social effects. The rationale was that most of the social issues raised regarding the use of tranquilizers dealt with long-term changes. If people took Valium to manage very brief episodes of anxiety (much like taking an aspirin for a headache), both the anxiolytic and social effects might be short-lived. Consequently, it is possible that, any anxiolytic effects might have been too short-lived to detect in this study. This is plausible because the strongest associations among use of Valium, anxiety, and quality of life occurred at lag zero and tended to decrease as the lags increased to one or more weeks. (Although clinical trials suggest that Valium's anxiolytic effects occur in as little as one week [15] , most trials focus on interventions of l-6 weeks rather than period's shorter than that. The package insert [27] does not indicate a specific minimum period of recommended anxiolytic use.)
The other side of this concern might be that if there were any social effects of Valium use, they might take longer to develop than the 6-month time span of this study. However, the lagged data described above indicated no such trend. Indeed, the magnitude of effects examined in this study decreased, rather than increased, with the passage of time.
It is also possible that, if there were any social or anxiolytic effects, they might have occurred prior to when people entered the study. Only prior measurement could have resolved this issue. However, new users of Valium and users who started and stopped taking Valium during the course of the study provided one opportunity to look at anxiety and social effects over a relatively short period of new or renewed use. Analyses of the small number of new users and of intermittent users did not alter the basic findings*.
No association between use of Valium and either anxiety or social effects would be likely to occur, even over the short run, if people took the medication prophylactically.
If people took Valium in anticipation of events that they perceived as potentially anxiety-provoking. then one might expect anxiety to be low both before and after taking Valium: other social effect outcomes also might be relatively unchanged. This study lacks the data required to evaluate this explanation.
and we are not aware of any other study which assessed the incidence and prevalence of prophylactic use.
*Another possible cxplanat~on ol'the results is that Valium use was effective in improvlng quality of lice. but no more so than anything else. This interpretation derives from case-by-case analyses of the data. Those analyses showed that. slier an increase in anxiety. anxiety generally decreased and quality 0T life generally increased. but no mow so when Valium was taken than when it was not. Only a placebo irkI can determine the validity ol' such an explana~wn.
Similarly, no association
between Valium use and anxiety or social effects would be detected if people were using alcohol and Valium in a complementary fashion to manage anxiety continuously.
However. when those taking alcohol (or other CNS stimulant or depressant drugs) were examined separately from those who were not taking such drugs. the overall results were unchanged.
A lack of association might also occur if users of Valium had levels of anxiety and depression that were not clinically responsive to the effects of a minor tranquilizer [34.35] . However, analyses of subgroups with different initial levels of anxiety and with different initial combinations of anxiety and depression did not alter the basic findings.
There is the possibility that social and anxiolytic effects were not detected because the measures were unreliable or invalid. This is refuted by the rigorous criteria that were used in developing the measures. Internal reliability was demonstrated in a variety of key subgroups including users and nonusers of Valium. Validity of the measures was demonstrated by bivariate and multivariate analyses which showed that measures of the stresses, social support.
performance, subjective health, anxiety, and quality of life were related to one another in marked, statistically significant and theoretically meaningful ways [36] . Furthermore. the simple, cross-sectional correlations between use of Valium and measures of distress were similar to those found in national random-sample surveys of the United States [5. 61. Finally, the lack of association between Valium use and the various measures of well-being might be valid only for the respondents in this study; the effects might be different for the larger population of Valium users. Although the results should be replicated on a random sample of users and nonusers of Valium (or of other minor tranquilizers), we find no specific reason for predicting that the resulting relations reported here would be different.
Links to clinical trials and implications for future research
For most competing explanations, we conducted subgroup analyses or made use of other statistical techniques to control for potential artifacts. In each case the basic findings of the study were unchangedValium use did not appear to have any effects on anxiety or on many other social psychological variables when the minimum time frame for measuring use of the medication and level of the effects was seven days and when the maximum interval was 6 months.
In view of the numerous clinical trials demonstrating the anxiolytic effects of Valium and similar benzodiazepines, the most probable conclusion is that Valium has no long-term social effects, either harmful of beneficial. within the time frames and range of social elects examined in this study.
Rigorous clinical trials are designed to rule out the many artifactual and competing explanations that we have just addressed.
On the other hand. such trials introduce conditions which are antithetical to a study of actual. nonexperimental use. Hence we suggest that clinical trials might be used in the post-market surveillance period to confirm findings which have been identified through field surveys. In this way, but not identical to, indices developed by other investigators.
Those details as well as the full content of the measures are available elsewhere (171. Also available are the details of the calendar measures of Valium use, quality of life, and anxiety which were used to obtain retrospective data and the details of the protocol for assessing medication use. These procedures are too complex to present here and require special materials.
